BIOMAT Database Logo BIOMAT Database Logo

Pulsatile administration of D1 but not D2 dopamine agonists induces behavioral tolerance in MPTP-treated monkeys. 1996

M R Luquin, and J Guillén, and I Legarda, and M Cruz Rodriguez, and L Del Rio, and J Dominguez, and J M Martínez-Lage
Department of Neurology, Clínica Universitaria, Medical School, Pamplona, Spain.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008252 Macaca fascicularis A species of the genus MACACA which typically lives near the coast in tidal creeks and mangrove swamps primarily on the islands of the Malay peninsula. Burmese Long-Tailed Macaque,Crab-Eating Monkey,Cynomolgus Monkey,M. f. aurea,M. fascicularis,Macaca fascicularis aurea,Monkey, Crab-Eating,Monkey, Cynomolgus,Crab-Eating Macaque,Burmese Long Tailed Macaque,Crab Eating Macaque,Crab Eating Monkey,Crab-Eating Macaques,Crab-Eating Monkeys,Cynomolgus Monkeys,Long-Tailed Macaque, Burmese,Macaque, Burmese Long-Tailed,Macaque, Crab-Eating,Monkey, Crab Eating
D008297 Male Males
D009068 Movement The act, process, or result of passing from one place or position to another. It differs from LOCOMOTION in that locomotion is restricted to the passing of the whole body from one place to another, while movement encompasses both locomotion but also a change of the position of the whole body or any of its parts. Movement may be used with reference to humans, vertebrate and invertebrate animals, and microorganisms. Differentiate also from MOTOR ACTIVITY, movement associated with behavior. Movements
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D010617 Phenanthridines
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson

Related Publications

M R Luquin, and J Guillén, and I Legarda, and M Cruz Rodriguez, and L Del Rio, and J Dominguez, and J M Martínez-Lage
Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
February 1995, The Journal of pharmacology and experimental therapeutics,
M R Luquin, and J Guillén, and I Legarda, and M Cruz Rodriguez, and L Del Rio, and J Dominguez, and J M Martínez-Lage
Differential therapeutic effects of dopamine D1 and D2 agonists in MPTP-induced parkinsonian monkeys: clinical implications.
January 1997, European neurology,
M R Luquin, and J Guillén, and I Legarda, and M Cruz Rodriguez, and L Del Rio, and J Dominguez, and J M Martínez-Lage
Caffeine cross-tolerance to selective dopamine D1 and D2 receptor agonists but not to their synergistic interaction.
September 1994, European journal of pharmacology,
M R Luquin, and J Guillén, and I Legarda, and M Cruz Rodriguez, and L Del Rio, and J Dominguez, and J M Martínez-Lage
Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
February 1999, Journal of neurochemistry,
M R Luquin, and J Guillén, and I Legarda, and M Cruz Rodriguez, and L Del Rio, and J Dominguez, and J M Martínez-Lage
Observational studies of dopamine D1 and D2 agonists in squirrel monkeys.
September 1994, Psychopharmacology,
M R Luquin, and J Guillén, and I Legarda, and M Cruz Rodriguez, and L Del Rio, and J Dominguez, and J M Martínez-Lage
Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset.
August 1992, Neuroscience letters,
M R Luquin, and J Guillén, and I Legarda, and M Cruz Rodriguez, and L Del Rio, and J Dominguez, and J M Martínez-Lage
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
April 2000, Experimental neurology,
M R Luquin, and J Guillén, and I Legarda, and M Cruz Rodriguez, and L Del Rio, and J Dominguez, and J M Martínez-Lage
Morphine and naltrexone modulate D2 but not D1 receptor induced motor behavior in MPTP-lesioned monkeys.
April 1995, Psychopharmacology,
M R Luquin, and J Guillén, and I Legarda, and M Cruz Rodriguez, and L Del Rio, and J Dominguez, and J M Martínez-Lage
The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
January 1993, Advances in neurology,
M R Luquin, and J Guillén, and I Legarda, and M Cruz Rodriguez, and L Del Rio, and J Dominguez, and J M Martínez-Lage
Differential effects of three dopamine receptor agonists in MPTP-treated monkeys.
January 1995, Journal of neural transmission. Parkinson's disease and dementia section,
Copied contents to your clipboard!